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Objective: In Denmark, the strategy for treatment of cancer with metastases to the liver has 
changed dramatically during the period 1998 to 2009, when multidisciplinary care and a number 
of new treatments were introduced. We therefore examined the changes in survival in Dan-
ish patients with colorectal carcinoma (CRC) or other solid tumors (non-CRC) who had liver 
metastases at time of diagnosis.
Study design and methods: We included patients diagnosed with liver metastases 
  synchronous with a primary cancer (ie, a solid cancer diagnosed at the same date or within 
60 days after liver metastasis diagnosis) during the period 1998 to 2009 identified through 
the Danish National Registry of Patients. We followed those who survived for more than 
60 days in a survival analysis (n = 1021). Survival and mortality rate ratio (MRR) at 1, 3, 
and 5 years stratified by year of diagnosis were estimated using Cox proportional hazards 
regression analysis.
Results: In the total study population of 1021 patients, 541 patients had a primary CRC and 
480 patients non-CRC. Overall, the 5-year survival improved from 3% (95% confidence interval 
[CI]: 1%–6%) in 1998–2000 to 10% (95% CI: 6%–14%) in 2007 to 2009 (predicted value). 
The 5-year survival for CRC-patients improved from 1% (95% CI: 0%–5%) to 11% (95% CI: 
6%–18%) whereas survival for non-CRC patients only increased from 5% (95% CI: 1%–10%) 
to 8% (95% CI: 4%–14%).
Conclusion: We observed improved survival in patients with liver metastases in a time period 
characterized by introduction of a structured multidisciplinary care and improved treatment 
options. The survival gain was most prominent for CRC-patients.
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Introduction
The liver is a common site of metastases and gastrointestinal-, lung- and breast cancers 
frequently give rise to liver metastases.1 Liver metastasis is usually considered to be a 
manifestation of end stage disease. However, in patients with colorectal cancer (CRC) 
metastases, the disease often presents with oligometastases relatively early on and the 
liver is often the only site of metastasis. Hence, at the time of CRC-diagnosis, 15% of 
patients have metastases to the liver and in approximately 75% of these, the metastases 
are confined to the liver.2 In general, systemic therapy is the preferred treatment for 
most patients with liver metastases, but patients with a limited number and size of 
the metastases and with favorable histology, especially CRC, should be considered 
for focal therapy.3–7 A large number of systemic therapies for patients with metastatic 
cancer have been introduced during the last 10 years and over the same period surgery Clinical Epidemiology 2011:3 (Suppl 1) submit your manuscript | www.dovepress.com
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and nonsurgical techniques for focal ablation of metastases 
in the liver have improved considerably.8
The Danish National Board of Health launched The 
National Cancer Treatment Plans I and II in 2000 and 2005 
aiming at improving cancer treatment in the country.9 The 
major issues were improvements in diagnostics, surgery, 
radiation therapy, and chemotherapy for cancer, and major 
government investments have followed the program. 
Assessing whether these efforts have resulted in real improve-
ment in terms of survival outcomes is thus of great interest. 
We therefore conducted a cohort study in Northern Denmark 
to study time changes in survival in patients with liver metas-
tases synchronously to CRC and non-CRC during 1998 to 
2009. We chose only to evaluate patients with synchronous 
liver metastases because metachronous metastases are known 
to be incompletely registered. Due to differences in biology 
and therapy options, the study evaluated patients with CRC 
and non-CRC liver metastases separately.
Material and methods
The study was conducted in the Central and the North 
Denmark Regions (2 of 5 Danish regions), with a combined 
population of 1.8 million. The National Health Service pro-
vides tax-supported health care for all inhabitants of Denmark, 
guaranteeing free access to hospitals. A 10-digit civil registra-
tion number has been assigned to all residents by the Central 
Office of Civil Registration since 1968.10 This number, unique 
to each Danish resident, is used in all Danish registries, allow-
ing unambiguous individual-level data linkage.
Identification of liver metastases  
cancer patients
Through the Danish National Registry of Patients (DNRP), 
we identified all patients who had a first time diagnosis 
of liver metastases in the period January 1, 1998 through 
December 31, 2009 and no previous cancer diagnosis 
recorded in the DNRP. DNRP contains information about 
all admissions from nonpsychiatric hospitals in Denmark 
since 1977.11 Outpatient and emergency room visits at hos-
pitals have been included since 1995. This registry includes 
information on civil registration number, dates of admission 
and discharge, surgical procedure(s) performed, and up to 20 
diagnoses from each hospital contact. Diagnoses have since 
1994 been classified according to the International Classi-
fication of Diseases (ICD) 10th edition. The ICD-10 codes 
used to identify patients with liver metastases was C78.7 
and additional codes used for identification of the primary 
cancers were C18-21 (CRC/anal cancer) and C00-17; and 
C22-97 (non-CRC).12 We restricted our study population to 
patients considered to have synchronous metastases, defined 
by being registered with a code for a primary cancer at date 
of liver metastasis diagnosis or within 60 days thereafter.
Survival
Survival status and eventual date of death for all included 
patients was obtained through the Civil Registration System. 
Since 1968, this system has kept electronic records, updated 
daily, on date of birth, date of emigration, and vital status 
for all residents. Data linkage was performed using the civil 
registration number as identification number.
Statistical analysis
Because we defined our population as patients with a pri-
mary cancer diagnosed at date of liver metastasis diagnosis 
or up to 60 days thereafter, we started our follow-up 60 days 
after metastasis diagnosis. We followed each patient until 
emigration, death, or 25 June 2010, whichever came first. 
To visualize crude survival we constructed Kaplan–Meier 
curves stratified according to period of diagnosis (1998–2000, 
2001–2003, 2004–2006, and 2007–2009). We estimated 1-, 
3-, and 5-year survival. In the latter periods we estimated 
3- and 5-year survival using a hybrid analysis in which we 
included the actual survival for as long as possible and then 
estimated the conditional probability of surviving thereafter 
based on the corresponding survival experience of patients in 
the previous period (ie, using a period analysis technique).13 
To compare mortality over time we used Cox proportional 
hazards regression analysis with 1998 to 2000 as the refer-
ence period to estimate the MRR and the corresponding 95% 
confidence interval (CI) adjusting for age (15–59 years, 60–74 
years, 75+ years) and gender. The assumptions of proportional 
Table 1 Patients with synchronous liver metastasis by primary 
tumor site, northern Denmark 1998 to 2009
Site Frequency Percent
Colorectal (CrC) 541 52.99
noncolorectal (non-CrC) 480 47.01
  Pancreas 144 14.10
  Lung, bronchi, and trachea 130 12.73
  Stomach 38 3.72
  Liver 27 2.64
  Breast 22 2.15
  Esophagus 21 2.06
  Kidney 19 1.86
  gallbladder and biliary tract 16 1.57
  Other 63 6.17
Total 1021 100.00
Abbreviation: CrC, colorectal carcinoma.Clinical Epidemiology 2011:3 (Suppl 1) submit your manuscript | www.dovepress.com
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hazards were examined graphically by plotting observed and 
simulated paths of the standardized score process.
Analyses were performed using SAS version 9.2 (SAS 
Institute Inc., Cary, NC).
Results
The study cohort comprised a total number of 1021 patients 
identified with synchronous liver metastases during the 12 
year period 1998 to 2009 in the Central and North Denmark 
Regions who all survived at least 60 days after date of 
diagnosis. The largest group of patients (n = 541; 53.0%) 
were diagnosed with CRC as primary cancer whereas the 
remaining non-CRC patients represented a variety of tumor 
sites (n = 480; 47.0%). In the same time period 15,097 
patients were registered with primary CRC (colon cancer 
or rectal cancer; ICD: C18-19 or C20-21) in the Central 
and North Denmark Regions. The distribution of patients 
according to the primary tumor site is listed in Table 1. The 
non-CRC group was dominated by patients with primary 
gastro-intestinal and lung cancer, whereas only 2.2% had a 
primary breast cancer. In the total cohort the median age was 
66.8 (range 15.3–95.3) years (Figure 1) with a male/female 
distribution of 54%/46%. The median age was 67.7 (range 
27.0–93.2) and 66.2 (range 15.3–95.3) years and the male/
female distribution 53%/47% and 55%/45% for the CRC and 
non-CRC cohorts, respectively.
For patients with synchronous liver metastases, the 
overall survival improved over the 12-year period (Table 2). 
This was most pronounced during 2007 to 2009. Over the 
time period 1998 to 2009, the 5-year survival improved 
from 3% (95% CI: 1%–6%) to 10% (95% CI: 6%–14%) 
(predicted value). The 5-year survival of CRC-patients 
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Figure 1 Age distribution of the total cohort of 1021 patients diagnosed with liver metastases, Denmark 1998 to 2009.
Table 2 1-, 3-, and 5-year overall survival and mortality rate ratio (Mrr) adjusted for age and gender for Danish patients with liver 
metastases stratified by period of diagnosis
Period of diagnosis
1998–2000 2001–2003 2004–2006 2007–2009
number of cancer patients 190 288 239 304
Median age (years) 67 67 66 68
1-year
Survival 22% (16%–28%) 25% (20%–30%) 24% (19%–30%) 30% (25%–36%)
Mrr 1 (reference) 0.96 (0.78–1.18) 0.88 (0.71–1.09) 0.76 (0.62–0.94)
Adjusted Mrr* 1 (reference) 0.98 (0.79–1.20) 0.87 (0.70–1.08) 0.74 (0.60–0.92)
3-year
Survival 5% (3%–9%) 7% (5%–11%) 5% (3%–9%) 12% (8%–16%)†
Mrr 1 (reference) 0.94 (0.78–1.13) 0.91 (0.75–1.10) 0.77 (0.63–0.93)†
Adjusted Mrr* 1 (reference) 0.96 (0.79–1.16) 0.91 (0.75–1.11) 0.75 (0.62–0.91)†
5-year
Survival 3% (1%–6%) 5% (3%–7%) 4% (2%–7%)† 10% (6%–14%)†
Mrr 1 (reference) 0.93 (0.77–1.13) 0.90 (0.74–1.09)† 0.76 (0.63–0.92)†
Adjusted Mrr* 1 (reference) 0.95 (0.79–1.15) 0.90 (0.74–1.10)† 0.75 (0.62–0.90)†
Notes: *Adjusted for age and gender; †Predicted values.Clinical Epidemiology 2011:3 (Suppl 1) submit your manuscript | www.dovepress.com
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improved from 1% (95% CI: 0%–5%) to 11% (95% CI: 
6%–18%) (Table 3) whereas the increase of survival for 
non-CRC patients was 5% (95% CI: 1%–10%) to 8% (95% 
CI: 4%–14%) (Table 4).
MRRs adjusted for age and gender in 2007 to 2009 were 
0.74 (95% CI: 0.60–0.92), 0.75 (95% CI: 0.62–0.91) and 0.75 
(95% CI: 0.62–0.90) after 1, 3, and 5 years, respectively, 
compared with 1998–2000 (Figure 2A, Table 2). For CRC 
patients (Figure 2B) the age and gender adjusted MRRs 
were 0.62 (95% CI: 0.45–0.85), 0.68 (95% CI: 0.52–0.88), 
and 0.66 (95% CI: 0.51–0.86) after 1, 3, and 5 years, respec-
tively, over the same time period (Table 3). For non-CRC 
patients the adjusted MRRs were 0.83 (95% CI: 0.62–1.11), 
0.82 (95% CI: 0.62–1.08), and 0.81 (95% CI: 0.62–1.07), 
respectively (Table 4).
Discussion
In this population-based study from Northern Denmark we 
found that the prognosis in patients with liver metastases 
diagnosed synchronously with CRC or other solid tumors 
improved from 1998 to 2009. Overall, 1-, 3- and 5-year mor-
tality decreased approximately 25% for the total group and 
among CRC patients the mortality decreased nearly 35%.
Different factors affected the interpretation of our results. 
We conducted a population-based study in a uniform health 
care system with a well-defined catchment area and had 
Table 3 1-, 3-, and 5-year overall survival and mortality rate ratio (Mrr) adjusted for age and gender for the cohort of colorectal 
carcinoma liver metastasis patients stratified by period of diagnosis
Year of diagnosis
1998–2000 2001–2003 2004–2006 2007–2009
number of cancer patients 103 158 120 160
Median age (years) 67 67 66 69
1-year
Survival 28% (20%–37%) 37% (30%–45%) 36% (27%–44%) 46% (37%–53%)
Mrr 1 (reference) 0.85 (0.63–1.15) 0.86 (0.62–1.18) 0.65 (0.48–0.89)
Adjusted Mrr* 1 (reference) 0.90 (0.67–1.22) 0.85 (0.61–1.17) 0.62 (0.45–0.85)
3-year
Survival 5% (2%–10%) 11% (7%–17%) 9% (5%–15%) 15% (9%–21%)†
Mrr 1 (reference) 0.82 (0.63–1.06) 0.86 (0.66–1.13) 0.69 (0.53–0.90)†
Adjusted Mrr* 1 (reference) 0.87 (0.67–1.12) 0.87 (0.66–1.15) 0.68 (0.52–0.88)†
5-year
Survival 1% (0%–5%) 6% (3%–11%) 6% (3%–12%)† 11% (6%–18%)†
Mrr 1 (reference) 0.79 (0.62–1.03) 0.84 (0.64–1.09)† 0.68 (0.52–0.88)†
Adjusted Mrr* 1 (reference) 0.84 (0.65–1.08) 0.87 (0.66–1.14)† 0.66 (0.51–0.86)†
Notes: *Adjusted for age and gender; †Predicted values.
Table 4 1-, 3-, and 5-year overall survival and mortality rate ratio (Mrr) adjusted for age and gender for the cohort of non-colorectal 
carcinoma liver metastasis patients stratified by period of diagnosis
Year of diagnosis
1998–2000 2001–2003 2004–2006 2007–2009
number of cancer patients 87 130 119 144
Median age (years) 65 65 65 67
1-year
Survival 14% (8%–22%) 10% (6%–16%) 13% (7%–19%) 14% (8%–20%)
Mrr 1 (reference) 1.11 (0.83–1.48) 0.81 (0.60–1.09) 0.83 (0.62–1.11)
Adjusted Mrr* 1 (reference) 1.11 (0.83–1.48) 0.81 (0.60–1.09) 0.83 (0.62–1.11)
3-year
Survival 6% (2%–12%) 2% (1%–6%) 2% (0%–5%) 8% (4%–14%)†
Mrr 1 (reference) 1.13 (0.86–1.50) 0.86 (0.65–1.15) 0.82 (0.62–1.08)†
Adjusted Mrr* 1 (reference) 1.13 (0.86–1.50) 0.87 (0.65–1.15) 0.82 (0.62–1.08)†
5-year
Survival 5% (1%–10%) 2% (1%–6%) 2% (.%–.%)† 8% (4%–14%)†
Mrr 1 (reference) 1.11 (0.84–1.46) 0.86 (0.65–1.14)† 0.82 (0.62–1.08)†
Adjusted Mrr* 1 (reference) 1.11 (0.84–1.47) 0.83 (0.62–1.10)† 0.81 (0.62–1.07)†
Notes: *Adjusted for age and gender; †Predicted values.Clinical Epidemiology 2011:3 (Suppl 1) submit your manuscript | www.dovepress.com
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Figure 2 Crude survival of A) the total patient cohort with synchronous liver metastases (n = 1021), B) the cohort of colorectal cancer (CrC)-patients with synchronous 
liver metastases (n = 541), and C) the cohort of non-CrC patients with synchronous liver metastases (n = 480), stratified by period of diagnosis.Clinical Epidemiology 2011:3 (Suppl 1) submit your manuscript | www.dovepress.com
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present study a multidisciplinary team was introduced for 
treatment of liver tumors and the therapy for liver tumors was 
evolving over the period. Historical studies have shown that 
long-term survival can be achieved in patients undergoing 
surgical resection of oligometastases to the liver.3–5 Patients 
who are technically operable should therefore be offered a 
surgical resection. Novel surgical techniques have increased 
the number of patients who are technically operable.16,17 
However, only approximately 25% of patients with CRC liver 
metastases are amenable to surgical resection.18 Nonsurgical 
ablation techniques, such as radiofrequency ablation or ste-
reotactic body radiation therapy are frequently used to treat 
patients with unresectable liver metastases in Denmark.19,20 
Still, the efficacy of surgery and nonsurgical tumor ablation 
has never been proven in randomized trials.
Traditionally, metastatic cancer is treated by systemic 
therapies and chemotherapy has improved considerably 
during the last decade. For CRC patients, chemotherapy 
and targeted therapy to patients with metastatic cancer may 
improve survival, lessen symptoms related to the disease, 
improve quality of life and downsize liver-only metastases in 
patients with nonresectable metastases that potentially may 
become resectable.21 And for patients with metastatic non-
CRC, new cytostatic agents, hormonal agents, and biological 
therapies have resulted in survival benefit.22
In conclusion our study indicates an improvement in 
survival for liver metastases patients during the 12 years 
from 1998 to 2009. The survival gain for CRC liver metas-
tasis patients may be a result of intensified efforts in the 
multidisciplinary care of patients who benefit from improved 
systemic therapy and more aggressive approach in resection 
or ablation of the liver metastases.
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